HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a price target of $90, as stated by analyst Joseph Pantginis.
June 04, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Viking Therapeutics and maintained a price target of $90. This positive analyst rating could boost investor confidence and potentially drive the stock price up in the short term.
The reiteration of a Buy rating and a high price target by a reputable analyst can positively influence investor sentiment and lead to an increase in the stock price. The $90 price target suggests significant upside potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100